Global Respiratory Distress Syndrome Market 2024 by Company, Regions, Type and Application, Forecast to 2030

Global Respiratory Distress Syndrome Market 2024 by Company, Regions, Type and Application, Forecast to 2030

Respiratory distress syndrome is caused by pulmonary surfactant deficiency in the lungs of neonates, most commonly in those born at < 37 weeks’ gestation. Risk increases with degree of prematurity. Symptoms and signs include grunting respirations, use of accessory muscles, and nasal flaring appearing soon after birth. Diagnosis is clinical; prenatal risk can be assessed with tests of fetal lung maturity. Treatment is surfactant therapy and supportive care. Treatment for RDS usually begins as soon as a newborn is born, sometimes in the delivery room. Treatments for RDS include surfactant replacement therapy, breathing support from a ventilator or nasal continuous positive airway pressure (NCPAP) machine, or other supportive treatments.

According to our (Global Info Research) latest study, the global Respiratory Distress Syndrome market size was valued at US$ 412 million in 2023 and is forecast to a readjusted size of USD 592 million by 2030 with a CAGR of 5.4% during review period.

North America is the largest consumption place, with a consumption market share nearly 33% . Following North America, China is the second largest consumption place with the consumption market share of 26%.The key manufacturers are Chiesi Farmaceutici, CR-Double Crane, ONY Biotech, AbbVie, Yuhan Corporation, JW Pharmaceuticals, Noargen etc. Top 3 companies occupied about 85% market share.

This report is a detailed and comprehensive analysis for global Respiratory Distress Syndrome market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2024, are provided.

Key Features:

Global Respiratory Distress Syndrome market size and forecasts, in consumption value ($ Million), 2019-2030

Global Respiratory Distress Syndrome market size and forecasts by region and country, in consumption value ($ Million), 2019-2030

Global Respiratory Distress Syndrome market size and forecasts, by Type and by Application, in consumption value ($ Million), 2019-2030

Global Respiratory Distress Syndrome market shares of main players, in revenue ($ Million), 2019-2024

The Primary Objectives in This Report Are:

To determine the size of the total market opportunity of global and key countries

To assess the growth potential for Respiratory Distress Syndrome

To forecast future growth in each product and end-use market

To assess competitive factors affecting the marketplace

This report profiles key players in the global Respiratory Distress Syndrome market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Chiesi Farmaceutici, CR-Double Crane, ONY Biotech, AbbVie, Yuhan Corporation, JW Pharmaceuticals, Noargen, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.

Market segmentation

Respiratory Distress Syndrome market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.

Market segmentation

Respiratory Distress Syndrome market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type
Poractant Alfa
Beractant
Calfactant
Others

Market segment by Application
Very Preterm Infants
Moderate to Late Preterm Infants
Others

Market segment by players, this report covers
Chiesi Farmaceutici
CR-Double Crane
ONY Biotech
AbbVie
Yuhan Corporation
JW Pharmaceuticals
Noargen

Market segment by regions, regional analysis covers

North America (United States, Canada and Mexico)

Europe (Germany, France, UK, Russia, Italy and Rest of Europe)

Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)

South America (Brazil, Rest of South America)

Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

The content of the study subjects, includes a total of 13 chapters:

Chapter 1, to describe Respiratory Distress Syndrome product scope, market overview, market estimation caveats and base year.

Chapter 2, to profile the top players of Respiratory Distress Syndrome, with revenue, gross margin, and global market share of Respiratory Distress Syndrome from 2019 to 2024.

Chapter 3, the Respiratory Distress Syndrome competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.

Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2019 to 2030.

Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2019 to 2024.and Respiratory Distress Syndrome market forecast, by regions, by Type and by Application, with consumption value, from 2024 to 2030.

Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.

Chapter 12, the key raw materials and key suppliers, and industry chain of Respiratory Distress Syndrome.

Chapter 13, to describe Respiratory Distress Syndrome research findings and conclusion.